Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844293 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
A Phase 1 study of FXI, sponsored by Sirnaomics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT05844293 is a Phase 1 study of FXI that is actively recruiting participants, run by Sirnaomics. The registered enrollment target is 40 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05844293, a Phase 1 study of FXI, is actively recruiting participants, sponsored by Sirnaomics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG FXI-GalNAc-siRNA
Study Locations (2)
Missouri
- BioPharma - Creve Coeur
Ontario
- BioPharma - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2024-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05844293
The ClinicalTrials.gov registry entry for NCT05844293 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirnaomics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with FXI appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05844293 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Ontario.
Frequently Asked Questions
What is clinical trial NCT05844293 about?
NCT05844293 is a clinical study titled "Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects". The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.
What is the current status of trial NCT05844293?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-05-16. Estimated completion is 2024-06.
What conditions does trial NCT05844293 study?
This clinical trial studies the following conditions: FXI.
What interventions are being tested in trial NCT05844293?
The interventions under investigation include: Placebo (OTHER), FXI-GalNAc-siRNA (DRUG).
Who is sponsoring clinical trial NCT05844293?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05844293 being conducted?
This trial has 2 study locations across Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.